0001070081-24-000021.txt : 20241107 0001070081-24-000021.hdr.sgml : 20241107 20241107161434 ACCESSION NUMBER: 0001070081-24-000021 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 241435907 BUSINESS ADDRESS: STREET 1: 500 WARREN CORPORATE CENTER DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 500 WARREN CORPORATE CENTER DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 8-K 1 tmb-20241107x8k.htm 8-K
0001070081false00010700812024-11-072024-11-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2024

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

Delaware

    

001-35969

    

04-3416587

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

500 Warren Corporate Center Drive

    

Warren, NJ

07059

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 222-7000

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PTCT

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On November 7, 2024, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference into this Item 2.02.

Item 7.01. Regulation FD Disclosure.

The Company will host a conference call on November 7, 2024, at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September 30, 2024, as well as other corporate highlights and updates. Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.

The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

    

Description

99.1

Press Release, dated November 7, 2024 issued by PTC Therapeutics, Inc.

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: November 7, 2024

By:

/s/ Pierre Gravier

Name:

Pierre Gravier

Title:

Chief Financial Officer

EX-99.1 2 tmb-20241107xex99d1.htm EX-99.1

Exhibit 99.1

PTC Therapeutics Provides Corporate Update and   
Reports Third Quarter 2024 Financial Results  
  

– Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million –

– Regulatory filings for sepiapterin, Translarna™ and AADC gene therapy under review by FDA –

– On track to achieve remaining 2024 clinical and regulatory milestones,

including NDA submission for vatiquinone –

WARREN, N.J., November 7, 2024 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2024.  

 

"I am proud of our team’s strong execution," said Matthew Klein, M.D., Chief Executive Officer. “We continue to achieve excellent revenue performance allowing us to raise full-year revenue guidance. In addition, we have submitted three approval applications to FDA so far this year, all of which have been accepted for review, and plan a fourth submission for vatiquinone for Friedreich ataxia in December. We are on our way to accomplishing all of our 2024 objectives and are in a strong financial position to execute on our long-term strategic plans.”   

Key Corporate Updates:  

Third quarter 2024 total revenue of $197 million
Third quarter 2024 revenue for the DMD franchise was $124 million
oTranslarna™ (ataluren) net product revenue was $72 million, driven by continued access for patients in existing geographies, continued geographic expansion, high compliance and adherence, and dose adjustments.
oEmflaza® (deflazacort) net product revenue was $52 million, driven by new patient starts, continued brand loyalty, high compliance and adherence, and dose adjustments.

Key Clinical and Regulatory Milestones:  

PTC submitted an NDA to the FDA for sepiapterin for the treatment of PKU. The file was accepted for review, and the regulatory action date is set for July 29, 2025.
PTC resubmitted the NDA for Translarna for the treatment of nmDMD; the file was accepted, and a regulatory action date was not provided.
The BLA for PTC’s gene therapy for AADC deficiency remains on schedule for a regulatory action date of November 13, 2024.
PTC received Fast Track Designation for the PTC518 Huntington’s disease program.
PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024.
PTC expects to share topline data for the CardinALS trial of utreloxastat for the treatment of ALS in the fourth quarter of 2024.

Third Quarter 2024 Financial Highlights:

Total revenues were $196.8 million for the third quarter of 2024, compared to $196.6 million for the third quarter of 2023.
Total revenue includes net product revenue across the commercial portfolio of $135.4 million for the third quarter of 2024, compared to $144.0 million for the third quarter of 2023. Total revenue also includes royalty and manufacturing revenue of $61.4 million in the third quarter of 2024, compared to $52.5 million for the third quarter of 2023.


Translarna net product revenues were $72.3 million for the third quarter of 2024, compared to $69.0 million for the third quarter of 2023.
Emflaza net product revenues were $51.9 million for the third quarter of 2024, compared to $67.4 million for the third quarter of 2023.
Roche reported Evrysdi® 2024 year-to-date sales of approximately CHF 1.2 billion, resulting in royalty revenue of $61.4 million to PTC for the third quarter of 2024, compared to $50.2 million for the third quarter of 2023.
Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $161.4 million for the third quarter of 2024, compared to $164.2 million for the third quarter of 2023. The decrease in research and development expenses reflects strategic portfolio prioritization, as PTC continues to focus its resources on its differentiated, high-potential R&D programs. Included in third quarter 2024 R&D expense is $50.0 million in regulatory success-based milestones related to the Censa acquisition.   
Non-GAAP R&D expenses were $152.0 million for the third quarter of 2024, excluding $9.4 million in non-cash, stock-based compensation expense, compared to $150.2 million for the third quarter of 2023, excluding $14.0 million in non-cash, stock-based compensation expense.
GAAP SG&A expenses were $73.5 million for the third quarter of 2024, compared to $80.9 million for the third quarter of 2023. The decrease in selling, general and administrative expenses reflects lower employee costs as a result of the reduction in workforce in 2023.
Non-GAAP SG&A expenses were $63.1 million for the third quarter of 2024, excluding $10.3 million in non-cash, stock-based compensation expense, compared to $67.9 million for the third quarter of 2023, excluding $13.0 million in non-cash, stock-based compensation expense.
Change in the fair value of deferred and contingent consideration was a loss of $0.7 million for the third quarter of 2024, compared to a loss of $1.5 million for the third quarter of 2023.
Tangible asset impairment and losses (gains) on transactions, net, was a loss of $1.8 million for the third quarter of 2024, compared to $0.0 million for the third quarter of 2023. These results were primarily related to fixed asset impairments.
Net loss was $106.7 million for the third quarter of 2024, compared to net loss of $133.0 million for the third quarter of 2023.
Cash, cash equivalents, and marketable securities was $1,013.4 million on September 30, 2024, compared to $876.7 million on December 31, 2023.
Shares issued and outstanding as of September 30, 2024, were 76,952,124.

PTC Updates Full Year 2024 Financial Guidance: 

PTC anticipates total revenues for full year 2024 to be between $750 million and $800 million.
PTC anticipates GAAP R&D and SG&A expenses for full year 2024 to be between $740 million and $835 million, including expected R&D expense milestone payments of up to $65 million. 
PTC anticipates non-GAAP R&D and SG&A expenses for full year 2024 to be between $660 million and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million. 
PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expenses. As of September 30, 2024, $85 million in milestones have been achieved, of which $65 million has been recorded as R&D operating expenses and $20 million as contingent consideration payable.   


Non-GAAP Financial Measures: 

In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.  


PTC Therapeutics, Inc. 
Consolidated Statements of Operations 
(In thousands, except share and per share data)

 

Three Months Ended September 30, 

Nine Months Ended September 30,

 

2024

2023

2024

2023

Revenues: 

 

 

 

 

 

 

 

Net product revenue 

 135,421 

 

 144,038 

 

 446,245 

 

 506,187 

Collaboration revenue 

 - 

 

 - 

 

 - 

 

 6 

Royalty revenue 

 61,365 

 

 50,173 

 

 145,702 

 

 117,857 

Manufacturing revenue 

 

 - 

 

 

 2,365 

 

 

 1,661 

 

 6,716 

Total revenues 

196,786 

 

 196,576 

 

593,608 

 

 630,766 

Operating expenses: 

 

 

 

 

 

 

 

Cost of product sales, excluding amortization of acquired intangible assets 

 10,848 

 

 9,493 

 

 41,115 

 

 36,368 

Amortization of acquired intangible asset 

 3,036 

 

 58,649 

 

 57,431 

 

 145,461 

Research and development (1) 

 161,412 

 

 164,212 

 

 409,710 

 

 545,210 

Selling, general and administrative (2) 

 73,456 

 

 80,886 

 

 216,228 

 

 256,249 

Change in the fair value of deferred and contingent consideration 

 700 

 

 1,500 

 

 5,700 

 

 (125,000) 

Intangible asset impairment  

 - 

 

 - 

 

 - 

 

 217,800 

Tangible asset impairment and losses (gains) on transactions, net 

 

 1,844 

 

 

 - 

 

 

 3,605 

 

 

 - 

Total operating expenses 

251,296 

 

 314,740 

 

733,789 

 

 1,076,088 

Loss from operations 

 (54,510) 

 

 (118,164) 

 

 (140,181) 

 

 (445,322) 

Interest expense, net 

 (41,609) 

 

 (28,160) 

 

 (125,933) 

 

 (84,905) 

Other expense, net 

 (1,872) 

 

 (20,266) 

 

 (2,306) 

 

 (8,832) 

Loss before income tax (expense) benefit 

 (97,991) 

 

 (166,590) 

 

 (268,420) 

 

 (539,059) 

Income tax (expense) benefit  

 (8,663) 

 

 33,620 

 

 (28,989) 

 

 68,247 

Net loss attributable to common stockholders 

 (106,654) 

 

 (132,970) 

 

 (297,409) 

 

 (470,812) 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding: 

 

 

 

 

 

 

 

Basic and diluted (in shares) 

76,925,523 

 

 75,377,997 

 

76,716,340 

 

 74,618,611 

Net loss per share—basic and diluted (in dollars per share) 

(1.39) 

 

 (1.76) 

 

(3.88) 

 

 (6.31) 

 

 

 

 

 

 

 

 

(1) Research and development reconciliation 

 

 

 

 

 

 

 

GAAP research and development 

 161,412 

 

 164,212 

 

 409,710 

 

 545,210 

Less: share-based compensation expense 

 9,416 

 

 13,986 

 

 27,810 

 

 44,828 

Non-GAAP research and development 

 151,996 

 

 150,226 

 

 381,900 

 

 500,382 

 

 

 

 

 

 

 

 

(2) Selling, general and administrative reconciliation 

 

 

 

 

 

 

 

GAAP selling, general and administrative 

 73,456 

 

 80,886 

 

 216,228 

 

 256,249 

Less: share-based compensation expense 

 10,339 

 

 12,956 

 

 29,566 

 

 40,300 

Non-GAAP selling, general and administrative  

 63,117 

 

 67,930 

 

 186,662 

 

 215,949 


PTC Therapeutics, Inc. 
Summary Consolidated Balance Sheets 
(in thousands, except share data)

 

 

 

 

 

 

 

September 30, 2024

December 31, 2023

Cash, cash equivalents and marketable securities 

 1,013,357 

 

 876,739 

Total assets 

 1,842,236 

 

 1,895,698 

 

 

 

 

 

 

Total debt 

 285,106 

 

 284,213 

Total deferred revenue 

 

 - 

 

 

 801 

Total liability for sale of future royalties 

 

 2,082,051 

 

 

 1,814,097 

Total liabilities 

  2,896,588 

 

 2,714,253 

 

 

 

 

 

 

Total stockholders' deficit (76,952,124 and 75,708,889 common shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively) 

 (1,054,352) 

 

 (818,555) 

Total liabilities and stockholders' deficit 

1,842,236 

 

 1,895,698 

 

 

 

 

 

 

PTC Therapeutics, Inc. 
Reconciliation of GAAP Milestone Payments Full Year 2024

(in millions)

 

 

Full Year 2024

 

(in millions)

 

 

Projected GAAP R&D Expense Related Milestone Payments 

 65 

Projected GAAP Contingent Consideration Payable Related Milestone Payments 

 

 25 

Total Projected GAAP Milestone Payments 

 90 

 

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&D and SG&A Expense 
(in millions)

 

 

 

 

 

 

 

 

Low End of Range

High End of Range

Projected GAAP R&D and SG&A Expense 

 740 

 

 835 

Less: projected non-cash, stock-based compensation expense 

 80 

 

 80 

Projected non-GAAP R&D and SG&A expense  

 660 

 

 755 

 


Acronyms:

AADC: Aromatic l-Amino Acid Decarboxylase

ALS: Amyotrophic Lateral Sclerosis

BLA: Biologics License Application

CHF: Confoederatio Helvetica Francs (Swiss francs)

DMD: Duchenne Muscular Dystrophy

FA: Friedreich Ataxia

FDA: U.S. Food and Drug Administration

GAAP: Generally Accepted Accounting Principles

HD: Huntington’s Disease

NDA: New Drug Application

nmDMD: Nonsense Mutation Duchenne Muscular Dystrophy

PKU: Phenylketonuria

R&D: Research and Development

SG&A: Selling, General, and Administrative

Today's Conference Call and Webcast Reminder:

To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, X, and LinkedIn.

For More Information:

Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406

jclemente@ptcbio.com

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "PTC Updates Full Year 2024 Financial Guidance", including with respect to (i) 2024 total revenue guidance, (ii) 2024


GAAP and non-GAAP R&D and SG&A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Commission adopts the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization for Translarna in the EEA, or PTC’s ability to identify other potential mechanisms by which it may provide Translarna to nmDMD patients in the EEA; PTC's ability to use the clinical data from its international drug registry study and real-world evidence concerning Translarna's benefits to support a continued marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC's ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC's interpretation of the results of clinical trials and the totality of clinical data from its trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to sepiapterin, including any regulatory submissions and potential approvals, commercialization, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under PTC’s SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC's preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC's strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or


maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi, Waylivra or sepiapterin.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.


EX-101.SCH 3 tmb-20241107.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 tmb-20241107_def.xml EX-101.DEF EX-101.LAB 5 tmb-20241107_lab.xml EX-101.LAB EX-101.PRE 6 tmb-20241107_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Nov. 07, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 07, 2024
Entity File Number 001-35969
Entity Registrant Name PTC THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-3416587
Entity Address, Address Line One 500 Warren Corporate Center Drive
Entity Address, City or Town Warren
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07059
City Area Code 908
Local Phone Number 222-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol PTCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001070081
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tmb-20241107.xsd tmb-20241107_def.xml tmb-20241107_lab.xml tmb-20241107_pre.xml tmb-20241107x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmb-20241107x8k.htm": { "nsprefix": "ptct", "nsuri": "http://www.ptcbio.com/20241107", "dts": { "schema": { "local": [ "tmb-20241107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "definitionLink": { "local": [ "tmb-20241107_def.xml" ] }, "labelLink": { "local": [ "tmb-20241107_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20241107_pre.xml" ] }, "inline": { "local": [ "tmb-20241107x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20241107x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_7_2024_To_11_7_2024_fsyQGPPYB06cDQwk60AVSg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20241107x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001070081-24-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001070081-24-000021-xbrl.zip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end XML 17 tmb-20241107x8k_htm.xml IDEA: XBRL DOCUMENT 0001070081 2024-11-07 2024-11-07 0001070081 false 8-K 2024-11-07 PTC THERAPEUTICS, INC. DE 001-35969 04-3416587 500 Warren Corporate Center Drive Warren NJ 07059 908 222-7000 false false false false Common Stock, $0.001 par value per share PTCT NASDAQ false